-- Suzhou Zelgen Biopharmaceuticals' (SHA:688266) third phase trial for recombinant human thyrotropin alfa for Injection achieved the prespecified primary endpoint for radioactive iodine remnant ablation in differentiated thyroid cancer patients without distant metastases, the company said in a Friday filing with the Shanghai bourse.
The study demonstrated non-inferior efficacy compared to conventional thyroid hormone withdrawal.
The company is planning to submit the drug for a biologics license application for the above indication.
Share of Suzhou Zelgen Biopharmaceuticals were down 3% in recent trade.